Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05011058 | An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas(NAVAL-1) | terminated | Phase 2 | 102 | Viracta Therapeutics, Inc.INDUSTRY | 14 | Jul 28, 2025 | clinicaltrials |
| NCT04493411 | Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI | terminated | N/A | 21 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 24, 2025 |
| clinicaltrials |
| NCT03401853 | Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma | terminated | Phase 2 | 18 | University of WashingtonOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT04125290 | US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)(PROXY) | terminated | — | 2 | AstraZenecaINDUSTRY | 1 | Jul 18, 2025 | clinicaltrials |
| NCT03287817 | Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma(ALEXANDER) | terminated | Phase 1 / Phase 2 | 52 | Autolus LimitedINDUSTRY | 2 | Jul 14, 2025 | clinicaltrials |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | terminated | Phase 2 | 31 | Roswell Park Cancer InstituteOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | terminated | Phase 1 | 55 | Biomea Fusion Inc.INDUSTRY | 5 | Jul 3, 2025 | clinicaltrials |
| NCT05442580 | CART-38 in Adult AML and MM Patients | terminated | Phase 1 | 11 | University of PennsylvaniaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04735471 | A Phase 1 Study of ADI-001 in B Cell Malignancies(GLEAN-1) | terminated | Phase 1 | 34 | Adicet TherapeuticsINDUSTRY | 1 | Jun 18, 2025 | clinicaltrials |
| NCT05027594 | Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 5 | Nerviano Medical SciencesINDUSTRY | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04986865 | A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas(PROBE) | terminated | Phase 1 | 31 | Antengene Biologics LimitedINDUSTRY | 2 | Jun 9, 2025 | clinicaltrials |
| NCT05265975 | A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL(SWATCH) | terminated | Phase 1 / Phase 2 | 54 | Antengene CorporationINDUSTRY | 1 | Jun 9, 2025 | clinicaltrials |
| NCT02420717 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia | terminated | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04034446 | CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) | terminated | Early Phase 1 | 2 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05405309 | RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia(CORONADO CLL) | terminated | Phase 1 / Phase 2 | 5 | University of UtahOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT01350258 | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps | terminated | Phase 1 / Phase 2 | 8 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04189952 | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma | terminated | Phase 2 | 2 | University of MiamiOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT05788289 | A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma | terminated | Phase 2 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT04892264 | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma | terminated | Phase 1 | 5 | Mayo ClinicOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT03400176 | VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib | terminated | Phase 1 | 39 | Novartis PharmaceuticalsINDUSTRY | 1 | May 16, 2025 | clinicaltrials |
| NCT03994705 | Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 20 | Cartesian TherapeuticsINDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT02966730 | Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy | terminated | Early Phase 1 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04556084 | Blinatumomab Bridging Therapy for BALL | terminated | Phase 2 | 2 | Michael BurkeOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT02823327 | Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma | terminated | — | 25 | AIDS Malignancy ConsortiumNETWORK | 1 | May 11, 2025 | clinicaltrials |
| NCT05833737 | Corneal Findings in Patients Treated With Belantamab Mafodotin | terminated | — | 12 | Medical University of ViennaOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives | terminated | Phase 2 | 4 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04892446 | Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 36 | Gilead SciencesINDUSTRY | 3 | May 2, 2025 | clinicaltrials |
| NCT01352312 | Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma | terminated | Phase 1 | 10 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04047797 | Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT03486067 | Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 183 | CelgeneINDUSTRY | 6 | Apr 17, 2025 | clinicaltrials |
| NCT03492125 | A Study Of The Selective PKC-β Inhibitor MS- 553 | terminated | Phase 1 / Phase 2 | 60 | MingSight Pharmaceuticals, IncINDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT03615105 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors | terminated | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04896658 | Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 10 | University of Maryland, BaltimoreOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT03871829 | Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab | terminated | Phase 2 | 88 | Janssen Research & Development, LLCINDUSTRY | 13 | Mar 30, 2025 | clinicaltrials |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | terminated | Phase 1 | 272 | IGM Biosciences, Inc.INDUSTRY | 5 | Mar 28, 2025 | clinicaltrials |
| NCT04975399 | Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 | 26 | CelgeneINDUSTRY | 3 | Mar 24, 2025 | clinicaltrials |
| NCT04419389 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)(R/R) | terminated | Phase 1 / Phase 2 | 1 | Aprea TherapeuticsINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04982471 | Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study | terminated | — | 36 | CelgeneINDUSTRY | 1 | Mar 11, 2025 | clinicaltrials |
| NCT03893682 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | terminated | Phase 1 | 36 | Aptose Biosciences Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT01997840 | ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 103 | CelgeneINDUSTRY | 1 | Mar 4, 2025 | clinicaltrials |
| NCT03457142 | Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy | terminated | Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT04750941 | Study of Copanlisib and Ketogenic Diet | terminated | Phase 2 | 1 | Columbia UniversityOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT02291965 | Blood Samples to Identify Biomarkers of Busulfan | terminated | — | 139 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06655818 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM | terminated | Phase 1 / Phase 2 | 4 | GlaxoSmithKlineINDUSTRY | 2 | Mar 3, 2025 | clinicaltrials |
| NCT04700176 | A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma | terminated | Phase 2 | 1 | Hackensack Meridian HealthOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT02761187 | An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants | terminated | — | 4,253 | TakedaINDUSTRY | 15 | Feb 24, 2025 | clinicaltrials |
| NCT04895917 | Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis(DarPAL) | terminated | Phase 2 | 27 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Feb 20, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jul 28, 2025source: clinicaltrials